Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour.
Biomarkers, Tumor
/ genetics
Female
Genetic Predisposition to Disease
/ genetics
Genome-Wide Association Study
/ methods
Humans
Membrane Glycoproteins
/ genetics
Membrane Transport Proteins
/ genetics
Ovarian Neoplasms
/ diagnosis
Polymorphism, Single Nucleotide
Risk Factors
Venous Thromboembolism
/ diagnosis
Cancer hallmarks
Clinical outcome
GWAS
Ovarian cancer
SNPs
Venous thromboembolism
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
19
08
2019
revised:
01
11
2019
accepted:
01
11
2019
pubmed:
7
11
2019
medline:
23
2
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Venous thromboembolism (VTE) is a common cardiovascular disease thought to be the outcome of an intricate interplay between acquired and inherited factors that act together to modify disease risk. Over the years, several single-nucleotide polymorphisms (SNPs) in candidate genes have been associated with disease risk, including F5 rs6025, F2 rs1799963, FGG rs2066865, ABO genetic variants, among others less common. More recently, genome-wide association studies (GWAS) have contributed to the identification of novel VTE-associated SNPs, some of them located in novel genes with no clear role in the haemostatic system, such as SLC44A2 rs2288904 and TSPAN15 rs78707713. Given the existence of a tight relationship between VTE and cancer, with both pathologies sharing biological pathways that allow one to promote the other, these SNPs constitute potential prognostic and predictive biomarkers currently needed for better management of cancer patients. Among solid tumours, ovarian cancer (OC) is one of the most frequently associated with VTE. Indeed, haemostatic components might have a significant impact in OC progression, and therefore, the clinical and biological implications of VTE-associated SNPs should be assessed in patients with this neoplasia.
Identifiants
pubmed: 31689458
pii: S0304-419X(19)30115-5
doi: 10.1016/j.bbcan.2019.188331
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Membrane Glycoproteins
0
Membrane Transport Proteins
0
SLC44A2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188331Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.